Understanding

What’s the Follow-Up Plan After a Clinical Trial?

What happens after a patient participates in a clinical trial for cancer treatment? Watch now to hear both patient and expert perspectives on post-trial follow-up care.

Published:

How Can Experts Overcome Language and Cultural Barriers to Increase Clinical Trial Participation?

How are researchers helping to improve participation by minorities in clinical trials? Watch as expert Dr. Richard Schilsky discusses language and cultural barriers.

Published:

Why Are Minorities Often Underrepresented in Clinical Trials?

How can ethnic minorities gain access to more clinical trials? Watch as clinical trial experts Dr. Richard Schilsky and Cecelia Mann share their perspectives.

Published:

Addressing a History of Fears About Clinical Trials: An Expert Weighs In

How are cancer patients cared for in clinical studies? Tune in to hear expert Dr. Richard Schilsky explain patient consent and safety, clinical trial regulation and more.

Published:

What Is the Role of Mindfulness in Cancer Care?

How are mindfulness-based practices used in cancer care? Watch as expert Dr. Ruben Mesa explains how techniques can help with stress reduction, managing uncertainty and more.

Published:

Dear Stacey: Are There Costly Consequences to Co-Pay Accumulator Programs?

What is a co-pay accumulator, and how will it affect cancer patients access to treatment? Noted healthcare attorney Stacey Worthy discusses what patients need to know about the “double-dip” insurance deductible.

Published:

Clinical Trial MythBusters: What Is the Value of Diversity in Clinical Trials?

Is diversity, gender, age and ethnicity important in clinical trials? Mel Mann, a 20+ year CML survivor and a a highly respected leader in the field of clinical oncology weigh in.

Published:

Will I Feel Like a Guinea Pig? A Four-Time Clinical Trial Participant Shares Her Experience

A common question patients have when considering a clinical trial is “will I be a guinea pig?” Meet Reina Weiner, a four-time clinical trial participant, as she shares her experience navigating the trial process, patient consent, safety, risks, family issues and more.

Published:

Can Low Clinical Trial Participation Inhibit Cancer Research and Innovation?

Lazarex chairman Dana Dornsife says that there’s a “48 percent failure rate of clinical trials, and it's not because the drug didn't work.” Why do some medicines never make it to market? Watch now to find out.

Published:

Showing 9 of 58 programs
Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on July 11, 2014